Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Case of Lassa fever challenges UK hospitals

This article was originally published in Clinica

Executive Summary

Testing to diagnose in the UK a rare, isolated case of a viral haemorrhagic fever had to be referred to the Health Protection Agency (HPA), after the standard battery of tests for diseases associated with African travel proved negative. Lassa fever was eventually diagnosed; the patient had returned from Nigeria in early January. Following admission to London's Homerton hospital on January 8, it was not until January 22 that the diagnosis was made, according to the HPA. "The Homerton carried out testing for a wide range of common infections associated with travel to Africa, all of which tested negative. Samples were [then] referred to the HPA," said the agency. Lassa fever is endemic to Nigeria, but infections have occurred in neighbouring West African countries; it is seen only rarely in the UK among travellers returning from the region.

You may also be interested in...



Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.

Win For Axonics As England’s NICE Says Rechargeable Neuromodulation Is Cost-Effective

Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.

Topics

UsernamePublicRestriction

Register

MT042035

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel